Zymeworks Total Assets 2016-2022 | ZYME

Zymeworks total assets from 2016 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Zymeworks Annual Total Assets
(Millions of US $)
2021 $389
2020 $538
2019 $368
2018 $244
2017 $132
2016 $94
2015 $23
Zymeworks Quarterly Total Assets
(Millions of US $)
2022-06-30 $369
2022-03-31 $430
2021-12-31 $389
2021-09-30 $420
2021-06-30 $472
2021-03-31 $490
2020-12-31 $538
2020-09-30 $572
2020-06-30 $607
2020-03-31 $637
2019-12-31 $368
2019-09-30 $400
2019-06-30 $415
2019-03-31 $238
2018-12-31 $244
2018-09-30 $194
2018-06-30 $211
2018-03-31 $114
2017-12-31 $132
2017-09-30 $100
2017-06-30 $115
2017-03-31 $80
2016-12-31 $94
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $23
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.480B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $171.581B 10.47
GSK (GSK) United Kingdom $71.504B 8.96
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.167B 19.06
Ginkgo Bioworks Holdings (DNA) United States $3.492B 0.00
Myovant Sciences (MYOV) United Kingdom $2.595B 0.00
Arcus Biosciences (RCUS) United States $2.459B 36.91
Biohaven (BHVN) United States $1.112B 0.00
Emergent Biosolutions (EBS) United States $0.588B 4.62
ADC Therapeutics SA (ADCT) Switzerland $0.270B 0.00
Enzo Biochem (ENZ) United States $0.092B 0.00
SQZ Biotechnologies (SQZ) United States $0.042B 0.00
Gelesis Holdings (GLS) United States $0.032B 0.00
Ambrx Biopharma (AMAM) United States $0.020B 0.00